Chung Goh Eun, Lee Jeong-Hoon, Kim Yoon Jun
Goh Eun Chung, Department of Internal Medicine, Healthcare Research Institute, Gangnam Healthcare Center, Seoul National University Hospital, Seoul 135-984, South Korea.
World J Gastroenterol. 2014 Jun 21;20(23):7306-11. doi: 10.3748/wjg.v20.i23.7306.
Chronic hepatitis B infection is associated with the development of cirrhosis, hepatocellular carcinoma, and finally liver-related mortality. Each year, approximately, 2%-5% of patients with hepatitis B virus (HBV)-related compensated cirrhosis develop decompensation, with additional clinical manifestations, such as ascites, jaundice, hepatic encephalopathy, and gastrointestinal bleeding. The outcome of decompensated HBV-related cirrhosis is poor, with a 5-year survival of 14%-35% compared to 84% in patients with compensated cirrhosis. Because the risk of disease progression is closely linked to a patient's serum HBV DNA level, antiviral therapy may suppress viral replication, stabilize liver function and improve survival. This article briefly reviews the role that antiviral therapy plays in cirrhosis complications, particularly, in decompensation and acute-on-chronic liver failure.
慢性乙型肝炎感染与肝硬化、肝细胞癌的发生发展以及最终的肝脏相关死亡率相关。每年，约2%-5%的乙型肝炎病毒（HBV）相关代偿期肝硬化患者会出现失代偿，伴有腹水、黄疸、肝性脑病和胃肠道出血等额外临床表现。HBV相关失代偿期肝硬化的预后较差，5年生存率为14%-35%，而代偿期肝硬化患者的5年生存率为84%。由于疾病进展风险与患者血清HBV DNA水平密切相关，抗病毒治疗可能会抑制病毒复制、稳定肝功能并提高生存率。本文简要综述了抗病毒治疗在肝硬化并发症，特别是失代偿和慢加急性肝衰竭中所起的作用。
